We have developed the next-generation tissue analysis system, based on upconverting nanoparticles (UCNPs). Lumito SCIZYS is a cutting-edge, high-sensitivity system combining labeling and imaging technologies to locate and measure biomarkers in tissue samples.
The company holds a broad patent portfolio of three patent families. Lumito’s solution enables quantitative and objective assessment of tissue samples, addressing a multitude of challenges in drug development and academic research.
Our foundation
A research group in the Division of Atomic Physics and Laser Centre at Lund University proved the advantages of a medical application of upconverting nanoparticles (UCNP). Their research launched what would later become Lumito AB.
Recent milestones
Lumito and Concept Life Sciences join forces to advance tissue analysis in drug discovery
Partnership agreement signed, with Truly Labs
Signing Paul Waring as Scientific Advisor
Letter of intent signed with Katana Labs
CEO Sanna Wallenborg started, Aug 2024
Scanner system launched, July 2024
Kerstin Jakobsson appointed Chair of the Board of Directors, May 2024